Christine S. Kim

Christine practices corporate and securities law, with an emphasis on private and public company representation and capital markets transactions. She represents private and public companies on a variety of securities offerings, including initial public offerings (IPOs), secondary and follow-on offerings, and private placements, particularly in the life sciences and technology industries. Christine also advises public companies on corporate and securities matters, including Exchange Act reporting obligations and corporate governance issues. She also serves as co-chair of Cooley’s Asian Pacific Islander Attorney Affinity Group.

Christine’s representative transactions include advising:

• Beta Bionics in its $234.6 million IPO and concurrent $17 million private placement
• Artiva Biotherapeutics in its $167 million IPO
• Structure Therapeutics in its $185.3 million IPO, $300 million private investment in public equity (PIPE) and $547.4 million follow-on offering
• Genelux Corporation in its $17 million IPO and $27.5 million follow-on offering
• Immunome in its $230 million follow-on offering
• Drata in its $200 million Series C financing
• Design Therapeutics in its $125 million Series B financing and $240 million IPO